Skip to main content

An effective and safe targeted therapy for treatment of Myasthenia gravis

Project description

Innovative tolerance technology for the treatment of autoimmune disease

Myasthenia gravis (MG) is one of the most common chronic autoimmune neuromuscular diseases that causes weakness in the skeletal muscles responsible for breathing and moving parts of the body. Currently, there is no cure for MG, which belongs to the so-called orphan (rare) diseases with an unmet medical need. Toleranzia is a Swedish pharmaceutical company that develops therapies directed at the intrinsic resources of the immune system to treat autoimmune diseases. Under the EU-funded TOL2 project it will address the need for a safe and effective treatment to cure MG. The tolerance technology behind the TOL2 project has the potential to be applied to therapies for other autoimmune diseases.

Call for proposal

H2020-SMEInst-2018-2020-1
See other projects for this call

Coordinator

TOLERANZIA AB
Address
Erik Dahlbergsgatan 11 A
411 26 Goteborg
Sweden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000